CN115151824A - SARS-CoV-2病毒的检测方法及检测试剂盒 - Google Patents
SARS-CoV-2病毒的检测方法及检测试剂盒 Download PDFInfo
- Publication number
- CN115151824A CN115151824A CN202180016690.8A CN202180016690A CN115151824A CN 115151824 A CN115151824 A CN 115151824A CN 202180016690 A CN202180016690 A CN 202180016690A CN 115151824 A CN115151824 A CN 115151824A
- Authority
- CN
- China
- Prior art keywords
- antibody
- cov
- sars
- kit
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241001678559 COVID-19 virus Species 0.000 title claims abstract description 213
- 238000001514 detection method Methods 0.000 title claims abstract description 94
- 239000003153 chemical reaction reagent Substances 0.000 title description 14
- 239000000427 antigen Substances 0.000 claims abstract description 163
- 102000036639 antigens Human genes 0.000 claims abstract description 163
- 108091007433 antigens Proteins 0.000 claims abstract description 163
- 238000000034 method Methods 0.000 claims abstract description 76
- 241000700605 Viruses Species 0.000 claims abstract description 22
- 239000000523 sample Substances 0.000 claims description 113
- 230000003612 virological effect Effects 0.000 claims description 59
- 239000007787 solid Substances 0.000 claims description 54
- 239000000243 solution Substances 0.000 claims description 52
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 48
- 238000005406 washing Methods 0.000 claims description 48
- 239000013641 positive control Substances 0.000 claims description 45
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 42
- 108091005634 SARS-CoV-2 receptor-binding domains Proteins 0.000 claims description 37
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims description 33
- 239000013642 negative control Substances 0.000 claims description 33
- 238000002965 ELISA Methods 0.000 claims description 31
- 229960002685 biotin Drugs 0.000 claims description 24
- 235000020958 biotin Nutrition 0.000 claims description 24
- 239000011616 biotin Substances 0.000 claims description 24
- 210000002966 serum Anatomy 0.000 claims description 21
- 239000000758 substrate Substances 0.000 claims description 21
- 108090000623 proteins and genes Proteins 0.000 claims description 18
- 238000011534 incubation Methods 0.000 claims description 16
- 102000012440 Acetylcholinesterase Human genes 0.000 claims description 15
- 108010022752 Acetylcholinesterase Proteins 0.000 claims description 15
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims description 15
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims description 15
- 238000008157 ELISA kit Methods 0.000 claims description 15
- 229940022698 acetylcholinesterase Drugs 0.000 claims description 15
- 108010005774 beta-Galactosidase Proteins 0.000 claims description 15
- 239000011248 coating agent Substances 0.000 claims description 15
- 238000000576 coating method Methods 0.000 claims description 15
- 102000004169 proteins and genes Human genes 0.000 claims description 15
- 241001112090 Pseudovirus Species 0.000 claims description 14
- 238000006243 chemical reaction Methods 0.000 claims description 14
- 239000007788 liquid Substances 0.000 claims description 13
- 239000003085 diluting agent Substances 0.000 claims description 11
- 239000012089 stop solution Substances 0.000 claims description 11
- 230000015572 biosynthetic process Effects 0.000 claims description 8
- 210000004369 blood Anatomy 0.000 claims description 8
- 239000008280 blood Substances 0.000 claims description 8
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 8
- 210000001519 tissue Anatomy 0.000 claims description 8
- 108010090804 Streptavidin Proteins 0.000 claims description 7
- 229920000592 inorganic polymer Polymers 0.000 claims description 7
- 229920000620 organic polymer Polymers 0.000 claims description 7
- 210000002381 plasma Anatomy 0.000 claims description 7
- 208000002151 Pleural effusion Diseases 0.000 claims description 6
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 6
- 108010039206 Biotinidase Proteins 0.000 claims description 5
- 239000012295 chemical reaction liquid Substances 0.000 claims description 5
- 206010036790 Productive cough Diseases 0.000 claims description 3
- 239000012472 biological sample Substances 0.000 claims description 3
- 230000028327 secretion Effects 0.000 claims description 3
- 210000003802 sputum Anatomy 0.000 claims description 3
- 208000024794 sputum Diseases 0.000 claims description 3
- 210000002700 urine Anatomy 0.000 claims description 3
- 102000005936 beta-Galactosidase Human genes 0.000 claims 5
- 238000003745 diagnosis Methods 0.000 abstract description 7
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 94
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 28
- 239000000872 buffer Substances 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 21
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 15
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 15
- 239000013612 plasmid Substances 0.000 description 14
- 239000011780 sodium chloride Substances 0.000 description 14
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 13
- 239000012634 fragment Substances 0.000 description 13
- 230000000903 blocking effect Effects 0.000 description 12
- 229940096437 Protein S Drugs 0.000 description 11
- 101710198474 Spike protein Proteins 0.000 description 11
- 102100026189 Beta-galactosidase Human genes 0.000 description 10
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 10
- 235000019799 monosodium phosphate Nutrition 0.000 description 10
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 10
- 238000001035 drying Methods 0.000 description 9
- 229940088598 enzyme Drugs 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 102100031673 Corneodesmosin Human genes 0.000 description 8
- 101710139375 Corneodesmosin Proteins 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 229920001213 Polysorbate 20 Polymers 0.000 description 7
- 238000002835 absorbance Methods 0.000 description 7
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 7
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 238000003118 sandwich ELISA Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 108020004705 Codon Proteins 0.000 description 6
- 241000711573 Coronaviridae Species 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 6
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 6
- 102000029301 Protein S Human genes 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 239000007853 buffer solution Substances 0.000 description 6
- 238000001962 electrophoresis Methods 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 6
- 230000009385 viral infection Effects 0.000 description 6
- 239000012224 working solution Substances 0.000 description 6
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 238000005457 optimization Methods 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 238000007789 sealing Methods 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 239000012124 Opti-MEM Substances 0.000 description 4
- 241000315672 SARS coronavirus Species 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 230000001588 bifunctional effect Effects 0.000 description 4
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 4
- 238000002038 chemiluminescence detection Methods 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000013613 expression plasmid Substances 0.000 description 4
- 238000003317 immunochromatography Methods 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 239000012679 serum free medium Substances 0.000 description 4
- 239000007790 solid phase Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 3
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 description 3
- 101710091045 Envelope protein Proteins 0.000 description 3
- 108060003393 Granulin Proteins 0.000 description 3
- 208000025370 Middle East respiratory syndrome Diseases 0.000 description 3
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 3
- 206010035664 Pneumonia Diseases 0.000 description 3
- 101710188315 Protein X Proteins 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000010009 beating Methods 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 239000012154 double-distilled water Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 3
- 235000019796 monopotassium phosphate Nutrition 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 229910052759 nickel Inorganic materials 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 239000001103 potassium chloride Substances 0.000 description 3
- 235000011164 potassium chloride Nutrition 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 241000008904 Betacoronavirus Species 0.000 description 2
- 208000025721 COVID-19 Diseases 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 208000001528 Coronaviridae Infections Diseases 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 101710172711 Structural protein Proteins 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 239000013060 biological fluid Substances 0.000 description 2
- 239000008366 buffered solution Substances 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- 229940039227 diagnostic agent Drugs 0.000 description 2
- 239000000032 diagnostic agent Substances 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000012470 diluted sample Substances 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000013399 early diagnosis Methods 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000012160 loading buffer Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102000053723 Angiotensin-converting enzyme 2 Human genes 0.000 description 1
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 1
- 241000112286 Bat SARS-like coronavirus Species 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
- 241000521257 Hydrops Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 101001028244 Onchocerca volvulus Fatty-acid and retinol-binding protein 1 Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 101000933967 Pseudomonas phage KPP25 Major capsid protein Proteins 0.000 description 1
- 101150010882 S gene Proteins 0.000 description 1
- 102000044437 S1 domains Human genes 0.000 description 1
- 108700036684 S1 domains Proteins 0.000 description 1
- 108091005609 SARS-CoV-2 Spike Subunit S1 Proteins 0.000 description 1
- 208000037847 SARS-CoV-2-infection Diseases 0.000 description 1
- 241000008910 Severe acute respiratory syndrome-related coronavirus Species 0.000 description 1
- 101800000904 Spike protein S1 Proteins 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000036046 immunoreaction Effects 0.000 description 1
- 238000003331 infrared imaging Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000004719 natural immunity Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- -1 polyethylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1002—Coronaviridae
- C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
属于病毒分子领域,涉及SARS‑CoV‑2病毒的检测方法及检测试剂盒,具体涉及一种检测样品中是否存在SARS‑CoV‑2病毒或其抗原的方法及其检测试剂盒。还涉及一种检测样品中是否存在抗SARS‑CoV‑2病毒抗体的方法及其检测试剂盒。进一步提供了一种特异性结合SARS‑CoV‑2病毒的抗体在检测试剂盒中的应用,所述抗体的重链序列如SEQ ID NO:6所示,和所述抗体的轻链序列如SEQ ID NO:7所示。所述的SARS‑CoV‑2检测方法操作简单且不需要特殊设备,能够实现病毒的早期免疫诊断。
Description
PCT国内申请,说明书已公开。
Claims (43)
- PCT国内申请,权利要求书已公开。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2020101282034 | 2020-02-28 | ||
CN202010128203 | 2020-02-28 | ||
PCT/CN2021/078179 WO2021170090A1 (zh) | 2020-02-28 | 2021-02-26 | SARS-CoV-2病毒的检测方法及检测试剂盒 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115151824A true CN115151824A (zh) | 2022-10-04 |
Family
ID=77490724
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202180016690.8A Pending CN115151824A (zh) | 2020-02-28 | 2021-02-26 | SARS-CoV-2病毒的检测方法及检测试剂盒 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN115151824A (zh) |
WO (1) | WO2021170090A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117203229A (zh) * | 2022-03-15 | 2023-12-08 | 慧壹科技(上海)有限公司 | 冠状病毒抗体及其用途 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1826356B (zh) * | 2003-07-22 | 2012-05-09 | 克鲁塞尔荷兰公司 | 针对sars冠状病毒的结合分子及其应用 |
CN101102794B (zh) * | 2004-11-11 | 2012-04-25 | 克鲁塞尔荷兰公司 | 抗sars-冠状病毒的组合物及其应用 |
-
2021
- 2021-02-26 CN CN202180016690.8A patent/CN115151824A/zh active Pending
- 2021-02-26 WO PCT/CN2021/078179 patent/WO2021170090A1/zh active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2021170090A1 (zh) | 2021-09-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100847586B1 (ko) | C형 간염 바이러스의 측정방법 | |
KR100916992B1 (ko) | B형 간염 바이러스 s 항원의 검출법 | |
JP7178224B2 (ja) | マイコプラズマ・ニューモニエの免疫学的検出法及びキット | |
CN107407679B (zh) | 肺炎支原体的免疫学检测法和试剂盒 | |
US20080254440A1 (en) | Anti-Sars Virus Antibody, Hybridoma Producing the Antibody and Immunoassay Reagent Using the Antibody | |
WO2021170090A1 (zh) | SARS-CoV-2病毒的检测方法及检测试剂盒 | |
CN112745387B (zh) | 抗猪塞尼卡谷病毒单克隆抗体及其应用 | |
JP6808178B2 (ja) | ヒトパルボウイルスb19抗原および抗体の同時検出方法及びキット | |
Li et al. | Characterization of novel Omp31 antigenic epitopes of Brucella melitensis by monoclonal antibodies | |
JP2006067979A (ja) | インフルエンザa型ウイルスの免疫検出法 | |
WO2022265065A1 (ja) | SARS-CoV-2の免疫測定方法及び免疫測定キット、並びにモノクローナル抗体又はその抗体断片 | |
US20040170953A1 (en) | Method for detecting or assaying hbv | |
WO2022102744A1 (ja) | SARS-CoV-2のスパイクタンパク質に対する抗体 | |
WO2019165019A1 (en) | Antibodies to human respiratory syncytial virus protein f pre-fusion conformation and methods of use therefor | |
JP4449171B2 (ja) | ヒトパルボウイルスb19抗原の免疫測定方法 | |
Zhang et al. | Development of a potential diagnostic monoclonal antibody against capsid spike protein VP27 of the novel goose astrovirus | |
KR20220055423A (ko) | SARS-CoV-2 특이적 신규 항체를 이용한 SARS-CoV-2의 검출방법 | |
Hernández et al. | Monoclonal and Polyclonal Antibodies as Biological Reagents for SARS-CoV-2 Diagnosis Through Nucleocapsid Protein Detection. | |
JP4619580B2 (ja) | 抗体捕捉法による抗体の免疫学的測定方法 | |
WO2022265066A1 (ja) | SARS-CoV-2の免疫測定方法及び免疫測定キット | |
KR101876535B1 (ko) | 소바이러스성 설사병 바이러스의 탐지용 항체, 이를 이용한 항원 검출 방법, 및 이를 포함하는 탐지키트 | |
CN110540598B (zh) | 基于流感嗜血杆菌表面蛋白抗体的流感嗜血杆菌Elisa检测试剂盒及制备方法 | |
WO2022244862A1 (ja) | ノロウイルスの免疫測定方法及び免疫測定器具 | |
WO2022244861A1 (ja) | 抗ノロウイルス抗体 | |
WO2022244860A1 (ja) | 抗ノロウイルス抗体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |